Development and validation of analytical method for Irbesartan and Atorvastatin by simultaneous equation spectroscopic method
A simple, accurate and precise spectroscopic method was developed for simultaneous estimation of Irbesartan and atorvastatin in synthetic mixture using simultaneous equation Method. In this spectroscopic method, 226.00 nm and 246.00 nm wavelengths were selected for measurement of absorptivity. Both the drugs show linearity in a concentration range of 05-30 μg/ml at their respective λmax. Accuracy, precision and recovery studies were done by QC samples covering lower, medium and high concentrations of the linearity range. The relative standard deviation for accuracy, precision studies were found to be within the acceptance range (<2%). The limit of determination was 0.033μg/ml and 0.125 μg/ml for Irbesartan and atorvastatin, respectively. The limit of quantification was 0.1008 μg/ml and 0.3792 μg/ml for Irbesartan and atorvastatin, respectively. Recovery of Irbesartan and atorvastatin were found to be 99.75 % and 99.52% respectively confirming the accuracy of the proposed method. The proposed method is recommended for routine analysis since they are rapid, simple, accurate and also sensitive and specific by no heating and no organic solvent extraction.
Asif H, Sabir AM and Parminder SB. A review of pharmacological and pharmaceutical profile of Irbesartan. Pharmacophore. 2(6); 2011: 276-86.
Irbesartan drug info in drugbank. (database available on internet): http://www.drugbank.ca/drugs/db01029
Irbesartan drug info. (database available on internet): http://en.wikipedia.org/wiki/irbesartan
Dileep N, Siva P, Santhi K and Sajeeth C. A review on atorvastatin co administration with ezetimibe for the treatment of hypercholesterolemia. Int J Pharm Chemica Sci. 1(2); 2012: 756-60.
Atorvastatin drug info in drugbank. (database available on internet): http://www.drugbank.ca/drugs/db01076
Virani P, Sojitra R, Raj H and Jain V. A review on Irbesartan co administered with Atorvastatin for the treatment of cardiac risk. J Crit Rev. 1(1); 2014: 25-28.
Antonio C, Roberta A, Roberto D. et al. Effect of atorvastatin and Irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation-American Heart Association. 111; 2013: 2517-24.
Virani P, Sojitra R, Raj H and Jain V. Irbesartan: A review on analytical method and its determination in pharmaceuticals and biological matrix. Inventi Rapid: Pharm Analysis & Quality Assurance. 4; 2014: 1-6.
Virani P, Sojitra R, Raj H and Jain V. Atorvastatin: A review on analytical method and its determination in pharmaceuticals and biological matrix. Inventi Rapid: Pharm Analysis & Quality Assurance. 4; 2014: 1-6.
Virani P, Raj H, Jain V and Jain P. Updated review: validation and method validation parameters. Pharmatutor. 2(10); 2014: 27-37.
Copyright (c) 2015 International Journal of Advances in Scientific Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).
- The author must Submit Copyright form After acceptance of Article.